Literature DB >> 24421077

Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis.

Beth M Beadle1, Kai-Ping Liao, Linda S Elting, Thomas A Buchholz, K Kian Ang, Adam S Garden, B Ashleigh Guadagnolo.   

Abstract

BACKGROUND: Intensity-modulated radiation therapy (IMRT) is a technologically advanced, and more expensive, method of delivering radiation therapy with a goal of minimizing toxicity. It has been widely adopted for head and neck cancers; however, its comparative impact on cancer control and survival remains unknown. The goal of this analysis was to compare the cause-specific survival (CSS) for patients with head and neck cancers treated with IMRT versus non-IMRT from 1999 to 2007.
METHODS: CSS was determined using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database and analyzed regarding treatment details, including the use of IMRT versus non-IMRT, using claims data. Hazard ratios (HRs) were estimated by the frailty model with a propensity score matching cohort and instrumental variable analysis.
RESULTS: A total of 3172 patients were identified. With a median follow-up of 40 months, patients treated with IMRT had a statistically significant improvement in CSS compared with those treated with non-IMRT (84.1% versus 66.0%; P < .001). When each anatomic subsite was analyzed separately, all respective subgroups of patients treated with IMRT had better CSS than those treated with non-IMRT. In multivariable survival analyses, patients treated with IMRT were associated with better CSS (HR = 0.72, 95% confidence interval = 0.59 to 0.90 for propensity score matching; HR = 0.60, 95% confidence interval = 0.41 to 0.88 for instrumental variable analysis).
CONCLUSIONS: Patients with head and neck cancers who were treated with IMRT experienced significant improvements in CSS compared with patients treated with non-IMRT techniques. This suggests there may be benefits to IMRT in cancer outcomes, in addition to toxicity reduction, for this patient population.
© 2013 American Cancer Society.

Entities:  

Keywords:  SEER-Medicare; head and neck cancer; intensity-modulated radiation therapy; oropharynx cancer; radiation oncology

Mesh:

Year:  2014        PMID: 24421077     DOI: 10.1002/cncr.28372

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  43 in total

1.  Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model.

Authors:  Vlad C Sandulache; Yunyun Chen; Heath D Skinner; Tongtong Lu; Lei Feng; Laurence E Court; Jeffrey N Myers; Raymond E Meyn; Clifton D Fuller; James A Bankson; Stephen Y Lai
Journal:  Mol Cancer Ther       Date:  2015-09-16       Impact factor: 6.261

2.  Increasing use of advanced radiation therapy technologies in the last 30 days of life among patients dying as a result of cancer in the United States.

Authors:  B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Thomas A Buchholz; Ya-Chen Tina Shih
Journal:  J Oncol Pract       Date:  2014-04-22       Impact factor: 3.840

3.  [Superiority of IMRT over conventional 3D-EBRT even with local control of the extremity].

Authors:  Frank Lohr; Anna Simeonova
Journal:  Strahlenther Onkol       Date:  2015-04       Impact factor: 3.621

Review 4.  Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.

Authors:  Janice Cho; Daniel E Johnson; Jennifer R Grandis
Journal:  Semin Radiat Oncol       Date:  2018-01       Impact factor: 5.934

5.  Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis.

Authors:  Jennifer A Schlichting; Nitin A Pagedar; Catherine Chioreso; Charles F Lynch; Mary E Charlton
Journal:  Cancer Causes Control       Date:  2019-05-22       Impact factor: 2.506

6.  Clinical impact of prolonged diagnosis to treatment interval (DTI) among patients with oropharyngeal squamous cell carcinoma.

Authors:  Sonam Sharma; Justin Bekelman; Alexander Lin; J Nicholas Lukens; Benjamin R Roman; Nandita Mitra; Samuel Swisher-McClure
Journal:  Oral Oncol       Date:  2016-03-16       Impact factor: 5.337

7.  Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.

Authors:  Saad Maqsood; Michael B Jameson; Charles De Groot; Cristian Hartopeanu; Nur Azri Bin Haji Mohd Yasin; Ziad Thotathil
Journal:  Cancer Rep (Hoboken)       Date:  2018-04-10

8.  Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis.

Authors:  Beth M Beadle; Kai-Ping Liao; Sharon H Giordano; Adam S Garden; Katherine A Hutcheson; Stephen Y Lai; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2016-09-23       Impact factor: 6.860

9.  Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.

Authors:  Clifton D Fuller; Abdallah S R Mohamed; Adam S Garden; G Brandon Gunn; Collin F Mulcahy; Mark Zafereo; Jack Phan; Stephen Y Lai; Jan S Lewin; Katherine A Hutcheson; Steven J Frank; Beth M Beadle; William H Morrison; Adel K El-Naggar; Esengul Kocak-Uzel; Lawrence E Ginsberg; Merril S Kies; Randal S Weber; David I Rosenthal
Journal:  Head Neck       Date:  2016-07-28       Impact factor: 3.147

10.  Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.

Authors:  Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-04-17       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.